Diabetic Macular Edema Epidemiology Analysis and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

In the 7MM total prevalent cases of diabetic macular edema epidemiology were 1,724,733 in 2021. The cases are expected to grow at an AGR of more than 1% during 2021-2031. Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The pathogenesis of ME is complex and multifactorial and mainly results from the disruption of the blood-retinal barrier, leading to the accumulation of fluid and serum macromolecules in the intercellular space.

DME market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for DME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of DME. The diagnosed prevalent cases of DME are further segmented by age (20 years and older), sex, involvement of the eye (center-involving DME and non-center-involving DME) and by type of DME (focal-pattern DME and diffuse-pattern DME). The following data describes epidemiology of DME.

Diabetic Macular Edema Epidemiology, Outlook

Diabetic Macular Edema Epidemiology, Outlook

For more insights, download a free report sample

Age-Specific 12-Month Diagnosed Prevalent Cases of DME

The key age segments in the 12-month diagnosed prevalent cases of DME are, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and more than 80. In 2021, for the 7MM combined, adults ages 60–69 years contributed the highest proportion of the diagnosed prevalent cases of DME.

Age-Specific 12-Month Diagnosed Prevalent Cases of DME

Age-Specific 12-Month Diagnosed Prevalent Cases of DME

For more key age segment insights, download a free report sample

COVID-19 Impact in the DME Epidemiology Market

The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences as global healthcare systems have been redirected to focus on fighting the pandemic. The impact of COVID-19 may include a shortage of medical staff, decreased access to treatment, a delay in diagnosis, decreased survival, and an increase in disease incidence related to coronavirus infections. Intravitreal therapy is widely recognized as a major milestone in ophthalmology, being one of the most commonly performed ocular procedures for DME. The spread of coronavirus disease led to a significant downsizing of non-urgent treatments provided for ocular disorders, including intravitreal therapy.

Market report overview

Market size 2021 1,724,733 cases
AGR% (2021-2031) >1%
Key age segments  20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and >80

Scope

  • The Diabetic Macular Edema (DME) Epidemiology Report and Model provide an overview of the risk factors and global trends of DME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME. The diagnosed prevalent cases of DME are further segmented by age (20 years and older), sex, and involvement of the eye (center-involving DME and non-center-involving DME) and by type of DME (focal-pattern DME and diffuse-pattern DME). The model associated with the report also provides the diagnosed prevalent cases of clinically significant DME among the diagnosed DME population.
  • The DME epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

  • The Diabetic Macular Edema (DME) Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global DME market.
  • Quantify patient populations in the global DME market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for DME therapeutics in each of the markets covered.
  • Understand magnitude of DME population

Table of Contents

| About GlobalData

1 Diabetic Macular Edema: Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 7MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Diagnosed prevalent cases of DME among the diagnosed DR population

2.4.4 Diagnosed prevalent cases of DME by involvement of the eye

2.4.5 Diagnosed prevalent cases of DME by type

2.5 Epidemiological forecast for DME (2021–31)

2.5.1 Diagnosed prevalent cases of DME among the diagnosed DR population

2.5.2 Age-specific diagnosed prevalent cases of DME among the diagnosed DR population

2.5.3 Sex-specific diagnosed prevalent cases of DME among the diagnosed DR population

2.5.4 Diagnosed prevalent cases of DME by involvement of the eye

2.5.5 Diagnosed prevalent cases of DME by type

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 COVID-19 impact

2.6.3 Limitations of the analysis

2.6.4 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 About the authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbid conditions associated with DME

Figures

Figure 1: 7MM, diagnosed prevalent cases of DME, both sexes, N, ages ≥20 years, 2021 and 2031

Figure 2: 7MM, diagnosed prevalence of DME (%), men and women, ages ≥20 years, 2021

Figure 3: 7MM, sources used and not used to forecast the diagnosed prevalent cases of DME

Figure 4: 7MM, sources used to forecast the diagnosed prevalent cases of DME by involvement of the eye

Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of DME by type

Figure 6: 7MM, diagnosed prevalent cases of DME, N, both sexes, ages ≥20 years, 2021

Figure 7: 7MM, diagnosed prevalent cases of DME by age group, N, both sexes, 2021

Figure 8: 7MM, diagnosed prevalent cases of DME by sex, N, ages ≥20 years, 2021

Figure 9: 7MM, diagnosed prevalent cases of DME by involvement of the eye, N, both sexes, ages ≥20 years, 2021

Figure 10: 7MM, diagnosed prevalent cases of DME by type, N, both sexes, ages ≥20 years, 2021

Frequently asked questions

Diabetic Macular Edema Epidemiology Analysis and Forecast, 2021-2031 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Diabetic Macular Edema Epidemiology Analysis and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Diabetic Macular Edema Epidemiology Analysis and Forecast, 2021-2031 in real time.

  • Access a live Diabetic Macular Edema Epidemiology Analysis and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.